Andrew W. Adams
Andrew Adams co-founded Oak HC/FT in 2014 to invest exclusively in healthcare and fintech entrepreneurs. In 2023, Oak HC/FT was named one of the ten best-performing venture capital firms in the world.
Andrew has spent over 25 years investing in leading healthcare companies. His investments include One Medical (NASDAQ: ONEM; acquired by Amazon), iHealthTechnologies (merged with Connolly), Therapy Brands (acquired by KKR), CLARiENT(acquired by GE Healthcare), PharMEDium Healthcare (acquired by CD&R), Limeade (ASX: LME; acquired by WebMD), Benefitfocus (NASDAQ: BNFT), CoreInformatics (acquired by Thermo Fisher), LDI (acquired by Diplomat Pharmacy), Maestro Health (acquired by AXA Group), CareMedic Systems (acquired byIngenix), American Esoteric Laboratories (acquired by Sonic HealthcareLimited), Argus Information & Advisory Services (acquired by VeriskAnalytics), Health Dialog (acquired by British United Provident Association), NetSpend Corporation (NASDAQ: NTSP; acquired by TSYS), PayFlex Systems(acquired by Aetna), United BioSource (acquired by Medco Health Solutions).
Andrew serves on the Boards of Akido, Artis BioSolutions, August Bioservices, Curana Health, DispatchHealth, Galileo, Infusion for Health, Marathon Health, Medical Home Network, Remodel Health, Reveleer, Rialtic, Trovo Health, and UnifiedWomen's Healthcare. He is actively involved with Noom and Precision MedicineGroup.
Andrew has been named one of the Top 25 Healthcare Investors of 2024 (GrowthCap). Andrew began his career at Alex Brown & Sons. He holds a Bachelor of Arts degree from Princeton University.
